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The microbiota, and the genes that comprise its microbiome, play key roles in human health. Host-microbe
interactions affect immunity, metabolism, development, and behavior, and dysbiosis of gut bacteria contrib-
utes to disease. Despite advances in correlating changes in the microbiota with various conditions, specific
mechanisms of host-microbiota signaling remain largely elusive. We discuss the synthesis of microbial me-
tabolites, their absorption, and potential physiological effects on the host. We propose that the effects of
specialized metabolites may explain present knowledge gaps in linking the gut microbiota to biological
host mechanisms during initial colonization, and in health and disease.Introduction
In the human body, microbial cells outnumber eukaryotic cells by
as many as ten to one (Savage, 1977) and contribute two orders
of magnitude more genes to the hologenome (Gill et al., 2006;
Turnbaugh et al., 2007). Their significance to host health and dis-
ease is thus unsurprising, although it was long overlooked. The
bacterial metagenome contributes to production of primary
metabolites and conversion of small molecules into secondary
metabolites, also called ‘‘specialized metabolites.’’ Products of
bacterial metabolism are believed to modulate human health in
many ways (Hooper et al., 2012, Blumberg and Powrie, 2012).
Crosstalk between microbial and human metabolites influences
processes such as nutrient and xenobiotic metabolism (Maurice
et al., 2013), protection against pathogens (Clarke et al., 2010),
regulation of the enteric nervous system (Soret et al., 2010), im-
mune regulation (Brestoff and Artis, 2013), resistance against
colorectal cancer (Hague et al., 1995; Hinnebusch et al., 2002;
Lan et al., 2007; Tang et al., 2011; Nicholson et al., 2012), and
complex neurological behavior (Hsiao et al., 2013) and also
affect lipid and cholesterol levels in serum (Berggren et al.,
1996; Delzenne and Williams, 2002). Metabolic pathways oper-
ating in the human body are thus the result of the combined
activities of the human genome and microbiome.
Diet is important to themicrobiota andmetabolome, as food is
a major source of precursors for metabolite production. Human-
ized mice fed a polysaccharide-deficient diet differed in both the
microbiome and metabolome from humanized mice on regular
chow (Marcobal et al., 2013). Conventionally raised mice fed
the same diet were also significantly different from conventional
mice fed regular chow or the humanized mice (Marcobal et al.,
2013). In humans, both long-term dietary patterns (Ridaura
et al., 2013; Wu et al., 2011) and rapid, extreme dietary changes
(Levy and Borenstein, 2014) are reflected in the microbial com-
munities and metagenome. In particular, amino acid intake cor-
relates with changes to microbial communities. For example,increased amino acid intake increased the relative abundance
of Bacteroidetes and changed the metabolome (Ridaura et al.,
2013; Wu et al., 2011). Individuals who ate a primarily animal-
based diet with little to no fiber for two days showed decreased
levels of acetate and butyrate in the gut compared to those who
consumed a plant-based diet over the same period (Levy and
Borenstein, 2014).
Energy balance depends on the diet, but also on the micro-
biome. Kwashiorkor, a severe form of malnutrition, can be trans-
ferred from affected people to mice by fecal transplantation
(Smith et al., 2013a). Specifically, fecal samples from human
twins, where one cotwin was malnourished and the other was
not, produced substantially different phenotypes in recipient
mice. Feeding the mice a traditional Malawi diet led to a loss of
30% of body mass in just three weeks in the mice that received
microbes from themalnourished cotwin, whilemice transplanted
from the healthy cotwin maintained normal body weight on this
diet. These differences in the microbiome were coupled to differ-
ences in amino acid, carbohydrate, and fat metabolism, even on
the same diet. Dietary responses also differed depending on the
microbiome: Ready-to-use Therapeutic Food, a nutrient-rich
and energy-dense dietary supplement, was able to rescue the
mice receiving the kwashiorkor microbiome from weight loss,
but produced little change in the mice receiving the healthy mi-
crobiome (Smith et al., 2013a). This study reflects the importance
of both microbiome composition and diet in determining the
metabolic profile, which, in turn, influences disease outcomes.
At the other metabolic extreme, obesity can also be modu-
lated by the gut microbiome, metabolome, and diet. Ridaura
et al. (2013) transferred microbes from lean and obese cotwins
into germ-free mice. The metagenomes of lean cotwins were en-
riched for genes encoding proteins that ferment complex carbo-
hydrates from plant sources. Cohousing lean and obese mice
mitigated the obese phenotype in a diet-dependent fashion. A
low-fat, high-plant polysaccharide diet promoted weight loss inCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 719
Figure 1. The Production-Absorption-
Target Site Pathway of Metabolites
A product of microbial metabolism from dietary or
metabolic precursors (A), specialized metabolites
are absorbed through epithelial barriers. A major
site for absorption of specializedmetabolites is the
intestine where metabolites cross the intestinal
epithelium and enter the circulation through the
portal vein, via the liver (middle panel). Once in the
circulation, metabolites travel to various target
sites (organs, tissue, cells, etc.) in the mammalian
host (B).
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low in plant materials did not significantly alter the obese pheno-
type of cohoused animals. Cohoused obese animals fed a
low-fat diet also differed in metabolite profiles from controls.
Conversely, the gut metagenome of ob/ob mice encodes for
many enzymes important for the initial steps of complex carbo-
hydrate metabolism (Turnbaugh et al., 2007). The result of this
enrichment is evident in increased carbohydrate fermentation
products (namely, propionate and butyrate) present in the
cecum of these mice. Clearly, the dietary source of indigestible
complex polysaccharides may influence on the effects the mi-
crobiome has on the host.
Commensal microbes, present at various mucosal surfaces of
the mammalian host, play a critical role in processing environ-
mental signals (e.g., diet, xenobiotics) and relaying ‘‘messages’’
to the epithelium and via the circulatory system. These
messages are classically thought of as microbial-associated
molecular patterns (MAMPS), common to various microorgan-
isms, or as metabolites involved in paracrine or endocrine
signaling to the host. Often, these metabolites can be beneficial.
For example, yet unknown secreted factors of commensal skin
bacteria can induce production of human antimicrobial peptides
such as defensins resulting in modulation of human innate im-
mune response (Wanke et al., 2011). An important function of
the human microbiome is to supply essential vitamins including
vitamin K, vitamin B12, biotin, folate, thiamine, riboflavin, and
pyridoxine, which are then absorbed by the intestines (Martens
et al., 2002; Said, 2011). Several recent reports have now identi-
fied specific microbial metabolites beyond those traditionally
associated with gut bacteria and may represent incipient ad-
vances in understanding the inextricable chemical link between
mammals and their microbiota. Likely, the vast majority of inter-
kingdom molecular communications remain unknown.
Here, we present pathways associated with the production of
primary and specialized metabolites and examine their possible
role in pathogenesis. We suggest a framework for studying and
understanding the role of specialized metabolites, focusing on
their production in the gut, followed by absorption, then circula-
tion to their target sites (Figure 1). Application of this framework
would allow better understanding of many pathologies and
potentially reveal new therapeutic targets.
Metagenome, Metatranscriptome, and Metabolites
The microbial metagenome links taxonomic identification to
metabolite production. Metagenomic analysis catalogs genes
within a microbial environment and helps provide mechanistic
explanations for metabolic changes associated with disease. A720 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.systems-level approach comparing themetagenomes of individ-
uals with obesity or inflammatory bowel disease (IBD) to healthy
controls suggested that the disease states were associated with
loss or gain of enzymes that served to initiate or terminate meta-
bolic pathways (Greenblum et al., 2012). Furthermore, shifts in
the microbial metagenome translate to changes in metabolic
profiles. Mice transplanted with microbes from obese humans
had a reduction in butyrate fermentation genes, along with
decreased butyrate levels in the cecum (Ridaura et al., 2013).
Horizontal gene transfer between species, and poor species-
level resolution in 16S rRNA gene sequencing, can limit the accu-
racy of direct metabolic predictions (Polz et al., 2013; Wang
et al., 2007), although coarse-grained predictions of metabolism
from the metagenome has still been useful in both host-associ-
ated and environmental contexts (Larsen et al., 2014).
Metagenome sequencing also shows how pathogenic organ-
isms adapt to polymicrobial infections in the host. Sequencing
Rothia mucilaginosa genomes from cystic fibrosis (CF) patients
and healthy controls revealed adaption by encoding multiple
genes for lactate dehydrogenase, enabling utilization of lactate
produced by the host and coinhabiting pathogens (Lim et al.,
2013). Other means of adaption included acquisition of genes
for phage lysins, modification of genes responsible for horizontal
gene transfer, and genes speculated to play roles in modula-
tion of biofilm formation, namely, CRISPR elements (Lim et al.,
2013). Metagenomic prediction could, potentially, be refined
through metatranscriptomic and metaproteomic analyses.
These methods may provide mechanistic insight into the regula-
tion of enzymes of interest, as the presence of a gene does not
guarantee expression of the corresponding protein product.
Bacterial protein expression is regulated at the transcriptional
and the translational level by many mechanisms (reviewed in
Berthoumieux et al., 2013; Quax et al., 2013). Thus expression-
level techniques may be especially useful in examining rapid
changes in bacterial function (Poretsky et al., 2009; McCarren
et al., 2010; Kolmeder et al., 2012). Integrating multi-meta-
omic techniques may provide many more direct links between
bacteria and their metabolites than are currently known.
Microbial Metabolite Synthesis Acts in Concert with
Host Metabolism
The best-studied microbial pathways influencing human health
involve production of short chain fatty acids (SCFAs) including
propionate, butyrate, and acetate. The end product of microbial
fermentation of complex nondigestible polysaccharide in the co-
lon (Cummings, 1983; Brestoff and Artis, 2013), SCFAs, and their
role in metabolism and immunity, have been appreciated for
Cell Metabolism
Perspectiveyears (see review by Brestoff and Artis, 2013). They contribute to
protection from infection and inflammation (Fukuda et al., 2011,
Maslowski et al., 2009, Kim et al., 2013), recruitment and matu-
ration of various subsets of immune cells (Arpaia et al., 2013,
Smith et al., 2013b, Sina et al., 2009), and metabolism (Bellah-
cene et al., 2013), and they mediate host-microbe interactions.
SCFAs interact with the host in several ways: via specific
G-coupled protein receptors (GPR)-41 and -43 (FFAR3 and 2,
respectively) (Brown et al., 2003; Le Poul et al., 2003), inhibiting
histone-deacetylases (HDAC) and thereby altering host gene
expression (Waldecker et al., 2008), and inducing autophagy
(Brestoff and Artis, 2013).
SCFAs have been implicated as a driver of obesity and dia-
betes (Fernandes et al., 2014). Cho et al. (2012) reported
increased levels of cecal SCFAs, resulting in increased hepatic
lipogenesis, in mice that have been treated with subtherapeutic
doses of antibiotics early in life. Interestingly, levels of glucose-
dependent insulinotropic polypeptide (GIP), but not other meta-
bolism-related hormones, were increased in treated mice. GIP
has been implicated to play a major role in obesity and diabetes
(e.g., Song et al., 2007, Nasteska et al., 2014). Much like GIP,
glucagon-like peptide (GLP-1) plays a role in obesity and dia-
betes, serving as a satiety signal and stimulating insulin release
after its secretion in the gut as a result of feeding (Madsbad,
2014). Intriguingly, levels of GLP-1 were reported to be regulated
via SCFA (specifically butyrate) production by the microbiota
(Wichmann et al., 2013, Yadav et al., 2013). Taken together,
these examples of microbiota regulation of metabolism via
metabolite production and hormonal regulation demonstrate
the major role that specialized metabolites play in host health.
Propionate production is especially important in human health,
promoting satiety, preventing liver lipogenesis, lowering choles-
terol, and providing anticarcinogenic activities (Havenaar,
2011). It was recently shown to take part in gut–brain communi-
cation as well as gluconeogenesis in the intestine (De Vadder
et al., 2014). Pathways leading to bacterial propionate formation
in the human gut have been extensively investigated using multi-
ple approaches (PCR amplification by degenerate primers, 16S
rRNA gene analysis, tblastn analysis, and microbial physiology),
highlightingdominantmicrobes andmicrobially influencedpropi-
onate pathways in the human gut (Reichardt et al., 2014). The
succinate pathway may be the most abundant pathway leading
to propionate formation in the human gut, as it is present both
in Bacteroidetes, the most abundant phylum in the gut, and the
less-abundant phylum Negativicutes. The biosynthetic route via
the propanediol pathway is found mostly in Lachnospiraceae
and may be the most important pathway utilizing deoxy-sugars
such as rhamnose and fucose from host glycans. The acrylate
pathway is the least widespread, and Coprococcus catus was
the first human gut bacterium in which this pathway was identi-
fied. Propionate and butyrate pathways mainly operate in phylo-
genetically distinct groups of anaerobic bacteria (Reichardt et al.,
2014). In general, caution should be used in predicting pathways
by in silico methods, because the presence of pathways may
simply indicate utilization of butyrate (e.g., coupled to methano-
genesis or sulfate reduction; Worm et al., 2014) rather than its
production (Ridaura et al., 2013; Vital et al., 2014). Further, the
importance of assessing the directionality of pathways along
with gene abundance was found to be critical in differentiatingbetween herbivores and carnivores (Muegge et al., 2011). Thus,
identifying the directionality may also be crucial for understand-
ing the link between microbes and metabolites. These findings
highlight that future studies deciphering roles of specific
microbial species in human health via biosynthetic pathways
from metagenomes should be performed via multiple ap-
proaches (Muegge et al., 2011; Reichardt et al., 2014).
Bacterial and host enzymes are linked into complex meta-
bolic pathways. For example, the neurotransmitter serotonin
(5-hydroxytryptamine) is a specialized metabolite synthesized
through the interaction between the host and its microbiome
(Figure 2). Approximately 90%of the serotonin in a human is syn-
thesized in the gastrointestinal tract (Berger et al., 2009), and
serotonin acts locally to regulate gastrointestinal, cardiac, respi-
ratory, and endocrine functions, as well as crossing the blood-
brain barrier (Berger et al., 2009; Nakatani et al., 2008). At the
most basic level, serotonin is derived from tryptophan by trypto-
phan hydroxylases -1 or -2 in a tetrahydrobiopterin-coupled
reaction, followed by a decarboxylation by amino acid decar-
boxylase (Walther et al., 2003; Sainio et al., 1996). Tryptophan
is an essential amino acid; it must be obtained from dietary or
microbial sources (Young, 1994). Germ-free (GF) mice have
lower levels of tryptophan, serotonin, and indoles than conven-
tionally raised or humanized (i.e., colonized with human micro-
biota) animals (Marcobal et al., 2013). Tryptophan is synthesized
from chorismate bymembers of several bacterial phyla including
Proteobacteria, Actinobacteria, and Firmicutes through en-
zymes whose genes are encoded in complex operons (Yanof-
sky, 2004; Xie et al., 2003; Figure 2). Escherichia coli can
synthesize chorismate, a tryptophan precursor, which acts as
a branch-point for many microbial metabolic pathways (LeBlanc
et al., 2013; Dosselaere and Vanderleyden, 2001). Bifidobacteria
are also predicted to have the capacity to synthesize chorismate
(LeBlanc et al., 2013). Consistent with this key role for bacteria,
antibiotic treatment altered tryptophan and indole metabolism
in rats (Zheng et al., 2011).
Short chain fatty acid and indole production are among the
better-characterized microbial metabolic pathways. They also
highlight different strategies in metabolic synthesis. SCFAs are
fermented from a variety of different sugars via distinct pathways
that do not intersect (Reichardt et al., 2014). Serotonin and tryp-
tophan biosynthesis are evolutionarily conserved (Radwanski
and Last, 1995) and reflect the interaction of host and microbial
symbionts in the production of specialized metabolites. These
examples may provide a framework for the characterization of
novel metabolic pathways: confirming metagenomic prediction
using integrated approaches including microbial genomics, mi-
crobial community analyses, and microbial physiology (Reich-
ardt et al., 2014).
Bioavailability of Microbial Metabolites
The mucosal epithelium regulates passage of essential nutrients
into circulation. The epithelium is composed of a single layer of
cells, dominated by enterocytes, that separate the gut lumen
from the underlying lamina propria. Tight-junction proteins
securely bind neighboring epithelial cells at the apical side and
regulate molecular transport (see reviews by Marchiando et al.,
2010, Peterson and Artis, 2014). Twomodes of transport through
the epithelium are possible: transcellular (through cells) andCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 721
Figure 2. Serotonin and Tryptophan Biosynthesis
Tryptophan biosynthesis begins with sugars from the pentose phosphate,
which are cyclized into Chorismate. Chorismate is a branch point and serves
as a precursor for Tryptophan. Intestinal epithelial cells convert tryptophan to
serotonin through a reduction and decarboxylation.
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specialized microbial metabolites, from small polar molecules
to larger peptides, affects their ability to withstand the intestinal
environment, as well as their capacity to cross the intestinal
epithelium into the circulation (Figure 1).
Pharmacokinetic concepts help describe the bioavailability of
microbial metabolites produced in the intestines (although it may
be challenging for metabolites like SCFAs that are derived from
various sources and may feed into different pathways, some of
which are yet unknown). In the healthy gut, a metabolite (or a722 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.drug) may be absorbed into circulation by passive or active
mechanisms. Based on their lipophilicity, size, and degree of
ionization (intestinal pH varies from 6.6 in the proximal small
intestine to 7.5 in the terminal ileum, and 6.4 in the cecum to
an average of 7 in the colon [Evans et al., 1988]), metabolites
may be absorbed by passive diffusion down a concentration
gradient. However, more hydrophilic metabolites cannot pene-
trate membranes easily. Some hydrophilic molecules reversibly
bind carriers that travel down concentration gradients, then
cross the epithelium via facilitated passive diffusion. Metabolites
(or drugs) that structurally resemble substrates that are shuttled
through the epithelial barrier, such as amino acids, sugars, and
vitamins, may be actively transported by the corresponding
transporters. Lastly, pinocytosis, the ingestion of fluid into cells,
may allow metabolite uptake. One example of transcellular
transport by facilitated diffusion is glucose, which is taken up
on the apical side of the lumen by a Na+/Glucose symporter
and transported from the basolateral side by the glucose trans-
porter-2 (GLUT2). SCFAs, on the other hand, may be transported
into epithelial cells and possibly through the epithelial barrier
either actively by monocarboxylate transporters (e.g., SLC5A8,
SLC16A1) or by diffusion (Ganapathy et al., 2013).
Some metabolites that cannot be absorbed by transcellular
transport (whether active or passive) are taken up by paracellular
transport. This type of transport is regulated by tight-junction
proteins. These proteins, primarily claudins, exclude molecules
based on size and charge (see review by Van Itallie and Ander-
son, 2006). Microbial metabolites may be actively transported
or diffuse through the healthy epithelial barrier, or conversely,
cross the barrier through paracellular transport when the epithe-
lial barrier is breached. ‘‘Leaky gut,’’ namely gut barrier dysfunc-
tion, is the result of dysbiosis and inflammation (Marchiando
et al., 2010). Interleukin-6 (IL-6), interferon-g (IFNg), and IL-1b-
induced barrier dysfunction (Suzuki et al., 2011; Al-Sadi et al.,
2010) is a known characteristic of IBD (Hollander et al., 1986).
Conversely, several probiotics have been shown to decrease
gut barrier permeability (Scaldaferri et al., 2012), and SCFAs
alone were sufficient to explain this effect (Elamin et al., 2013).
The gut lumen is a challenging environment for metabolites
such as peptides and small molecules. Before crossing the
epithelial barrier, a metabolite may be degraded or taken up by
microbes in the gut, or it may undergo various modifications.
The rate of these processes and the rate of a metabolite’s ab-
sorption to circulation interact to determine its bioavailability.
Subsequently, metabolites, as do drugs, may undergo detoxifi-
cation by the liver and kidney and may be excreted from circula-
tion. Xenobiotic metabolism may also alter the physiology and
gene expression of the host. Microbial metabolism of drugs is
exploited to convert prodrugs to active ingredients and is also
known to be associated with drug-induced toxicity (Li and Jia,
2013, Maurice et al., 2013). Alternatively, microbial metabolism
of xenobiotics may inactivate drugs. Digoxin, a cardiac drug, is
metabolized by Eggerthella lenta, a gut bacterium (Haiser
et al., 2013). Interestingly, dietary protein inhibits digoxin meta-
bolism by this bacterium in vivo and increases digoxin concen-
tration in serum and urine.
The circulatory system is structured such that any blood flow-
ing from the gut flows to the liver via the portal vein, through a
network of liver sinusoids, and out of the hepatic veins to the
Figure 3. Specialized Metabolites, Synthesized by the Gut Microbial
Community from Various Precursors, Reach Target Sites and
Mediate Health and Disease
SCFA: short-chain fatty-acids; TMAO: trimethylamine N-oxide; DCA: deoxy-
cholic acid; 4EPS: 4-ethylphenyl sulfate.
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late matter and bacteria that enter through the intestines. The
route of absorption differs for different metabolites; soluble
metabolites and nutrients are absorbed and enter the circulation
through the portal vein, but insoluble, fat-based metabolites are
most commonly absorbed into the lymphatic system and into the
bloodstream through the thoracic duct (Hall and Guyton, 2010).
Taken together, the pharmacokinetic properties of a metabo-
lite, from production and stability in the gut through absorption
and excretion, define its window of opportunity to act in driving
health or disease in the mammalian host.
Specialized Microbial Metabolites that Mediate Disease
The microbiome plays an important role in health and disease
(previously reviewed by Lee and Mazmanian, 2010; Clemente
et al., 2012). A shift in balance between a healthy and dysbiotic
microbiome leads to pathologic and metabolic conditionsincluding obesity, colon cancer, and IBD. Host-microbial interac-
tions are in part mediated by the immune response (Round and
Mazmanian, 2009), and possibly via specialized metabolites (Ur-
sell et al., 2014). The gut microbiota is a source for many hor-
mones and has been termed ‘‘a virtual endocrine organ’’ (Clarke
et al., 2014) that produces myriad secondary metabolites. Some
of these metabolites have positive effects on the mammalian
host, as in the case of SCFAs, mainly butyrate and acetate,
and antibiotics (e.g, Arpaia et al., 2013, den Besten et al.,
2013, Smith et al., 2013b, Furusawa et al., 2013, Fukuda et al.,
2011). Although dysbiosis of the host-associated microbiota
has been implicated in various conditions (Lee and Mazmanian,
2010; Clemente et al., 2012), the mechanisms by which specific
microbes, or microbial communities, induce disease remain
largely unknown. It is possible that specialized metabolites
may mediate many physiological states of well-being and illness
(Figure 3).
Microbial Metabolites and Cardiovascular Disease
Gut microbes contribute to atherosclerosis from dietary con-
sumption of red meat, providing a compelling example of micro-
bial metabolism leading to disease in the human host (Wang
et al., 2011; Koeth et al., 2013). Comparative levels of choline, tri-
methylamine N-oxide (TMAO), and betaine, three metabolites of
dietary phosphatidylcholine, predicted cardiovascular disease
risk in a clinical cohort and promote atherosclerosis in mice.
Concentrations of these metabolites also correlated with micro-
bial activity in the gut—administration of antibiotics suppressed
their production, and conventionalization with mouse gut mi-
crobes rescued the phenotype (Wang et al., 2011). Trimethyl-
amine (TMA), the precursor of TMAO, is also the product of
microbial metabolism of L-carnitine, a compound abundant in
red meat (Koeth et al., 2013). Interestingly, vegans and vegetar-
ians consuming L-carnitine producedmuch less TMAO than om-
nivores. Specific gut bacterial taxa also correlated with plasma
TMAO levels. Finally, supplementing mouse diets with L-carni-
tine markedly increased plasma levels of TMA and TMAO and
accelerated atherosclerosis. The mechanism by which TMAO
accelerates atherosclerosis is unknown, but it may contribute
to forward cholesterol transport via upregulation of macrophage
scavenger receptors. These studies demonstrate how a metab-
olite made by the gut bacterial community enters circulation and
contributes to disease. Moreover, ‘‘western’’ (high-fat) diets
have been associated with intestinal permeability (Martinez-
Medina et al., 2014), which would facilitate the absorption of mi-
crobial metabolites into the circulatory system.
Microbial Metabolites and Cancer
Gut microbes also play a role in carcinogenesis, especially in
colorectal cancer (see reviews by Bultman, 2014, Schwabe
and Jobin, 2013, and Sears and Garrett, 2014). Both the whole
gut microbial community and specific bacteria at specific times
play a role in initiating or exacerbating cancer (Kostic et al., 2012,
2013; Zackular et al., 2013; Ahn et al., 2013; Belcheva et al.,
2014). Fusobacterium nucleatum is enriched in human colonic
adenomas relative to surrounding tissue, suggesting that it
may play a role in early initiation of colorectal cancer (Kostic
et al., 2012, 2013). Further supporting this idea, F. nucleatum
colonization promoted and exacerbated tumorigenesis in the
gut of APCmin/+ mice, although the mechanism of pathogenesis
remains unknown.Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 723
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increase disease susceptibility and incidence. Risk factors for
colorectal cancer include high alcohol consumption and low
folate intake. Homann et al. (2000) fed rats normal diets and
administered high ethanol with or without antibiotics. Ethanol
led to increased acetaldehyde and decreased folate levels in
the colon. This effect was prevented by antibiotic treatment, sug-
gesting that ethanol degradation by gut microbes might play a
role in inducing colon cancer. Similarly, liver cancer likely involves
a complex interaction between obesity, gut microbes, and their
metabolites. In a model for liver cancer where neonate mice
were injected with a chemical carcinogen (7,12-dimethylbenz-
alpha-anthracene), genetic- or diet-induced obesity led to
changes in the gut microbiome of treated mice, and increased
levels of the metabolite deoxycholic acid (DCA), a known DNA
damaging agent. The induction of hepatocellular cancer could
be prevented by treatment with a cocktail of four antibiotics, or
by vancomycin alone. DCA levels were significantly increased
by high-fat diet (or in ob/ob mice), compared to wild-type ani-
mals, and addition of DCA to antibiotic-treated mice rescued
the tumor phenotype in these mice (Yoshimoto et al., 2013).
Microbial enzymes in the gut may also act on xenobiotics (such
as cancer chemotherapies) and induce various side effects. Wal-
lace et al. (2010) demonstrated that the antineoplastic drug
camptothecin (and its derivative CPT-11), inactivated in the liver,
causes severe diarrhea as a result of its reactivation in the gut
by bacterial b-glucuronidases. This could be prevented either
by antibiotic treatment (Flieger et al., 2007) or by specific b-glucu-
ronidases inhibitors (Wallace et al., 2010). These studies reveal a
chemical link betweengutmicrobes and cancer andalso suggest
a potential new treatment modality for disease by targeting
microbial processes during carcinogenesis.
Microbial Metabolites and Cystic Fibrosis
In cystic fibrosis (CF), the airway is abnormally colonized by poly-
microbial communities that vary among patients. These commu-
nities are affected by the conditions and nutrients available in CF
lungs. Different microbial communities differ in physiology and
metabolite production: even the same microbe may produce
different metabolites in the context of different communities.
For example, an increase in 2,3-butanedione concentrations
was observed in four of seven CF patients when compared to
healthy and ambient air controls (Whiteson et al., 2014); the three
patients with normal levels were undergoing antibiotic treat-
ments. Similarly, 2,3-butanedione levels decreased when the
other patients also underwent antibiotic treatment, suggesting
that microbes are involved in the production of this compound.
Streptococcusspp.was thedominant speciescarryinggenesen-
coding 2,3-butanedione biosynthesis, whereas genes for utilizing
butanedione pathway products were encoded by Pseudomonas
aeruginosa and Rothia mucilaginosa. Coculture experiments
suggested that P. aeruginosa, upon consumption of 2,3-butane-
dione produced byStreptococcus spp, enhanced the production
of redox carriers, namely, phenazines. Phenazines generate
reactive oxygen species in the presence of high oxygen tension
(i.e., high oxygenpartial pressure) andprovide additional electron
acceptors to the colonizing microbial community of the CF lung
as oxygen is depleted (Venkataraman et al., 2014).
A recent study based on metagenomes and metatranscrip-
tomes of microbial communities in sputum of CF-patients sug-724 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.gested a gradient of different communities, and hence of which
biochemical pathways were operational, based on oxygen avail-
ability (Quinn et al., 2014). Of particular interest is the shift of
pathways corresponding to microaerophilic respiration by Pseu-
domonas spp. to denitrification by Pseudomonas and Rothia
spp., and anaerobic respiration via reduction of various sulfur
species on depletion of oxygen. Other anaerobic pathways cor-
responded to acetate, butyrate, and butanediol fermentation.
Furthermore, enrichment in amino acid catabolism correlated
with elevated ammonia concentration, previously observed in
the sputum of CF patients. Interestingly, genes encoding folate
biosynthesis pathways were abundant in samples from the CF
population but absent in healthy controls. The CFmicrobial com-
munity may thus evolve in response to the administration of
sulphonamide drugs, which target folate biosynthesis. These
findings demonstrate how to evaluate likely physiological roles
and biochemical pathways of a microbial community and its
adaptation to disease environments.
Microbial Metabolites and Behavior
The gut microbiome-brain axis is an active area of research
(Bravo et al., 2011; Borre et al., 2014; De Palma et al., 2014)
and has received much attention recently. Observations that
brain development and behavior are influenced by the gut micro-
biota (Bravo et al., 2011; Diaz Heijtz et al., 2011; Gareau et al.,
2011; Neufeld et al., 2011 and others), and that this impact
may be transmitted from the enteric nervous system to the cen-
tral nervous system via the vagus nerve (e.g.; Bravo et al., 2011),
make metabolites produced in the gut the immediate suspects
for mediating gut microbiota-brain interactions.
Some bacteria can produce neuroactive metabolites, ranging
from serotonin and gamma-aminobutyric acid (GABA), to dopa-
mine and norepinephrine, to acetylcholine and histamine (see
Lyte, 2013; Roshchina 2010; Wall et al., 2014). GABA, for
example, is an inhibitory neurotransmitter that regulates and
participates in various functions in the central nervous system
in mammals and is involved in anxiety and depression. Barrett
et al. (2012) reported the production of GABA through meta-
bolism of monosodium glutamate by Bifidobacteria and lactoba-
cillus spp. isolated from the human gut. However, GABA from the
gut cannot cross an unbreached blood-brain barrier (Elliott and
Van Gelder, 1958). Another connection is that probiotic treat-
ment with Lactobacillus rhamnosus increases GABA receptor
expression in the hippocampus and reduces anxiety- and
depression-related behaviors in a mouse model (Bravo et al.,
2011).
No complete bacterium-metabolite-target pathway has yet
been definitively linked to behavioral changes. However, differ-
ences in microbial communities are often correlated with
changes in the metabolite profile, and perhaps behavior (e.g.;
Daniel et al., 2014; Hsiao et al., 2013). In a maternal immune
activation (MIA) mouse model for autism spectrum disorders
(ASD), both fecal bacterial communities and serum metabolo-
mic profiles are different between animals displaying altered
versus normal behavior (Hsiao et al., 2013). MIA mice also
exhibit autistic-like behavioral phenotypes (increased anxiety,
increased repetitive behavior, decreased sociability, and
decreased vocalization) and increased gut barrier dysfunction.
Interestingly, administration of a probiotic, Bacteroides fragilis
NCTC 9343 (a putative probiotic that is a human commensal
Cell Metabolism
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restored levels of some serum metabolites. One of these
metabolites, namely, 4-ethylphenylsulfate (4-EPS), was suffi-
cient to induce anxiety-like behaviors in mice when injected
into the circulation. B. fragilis, which contributes to a gut
microbial community that produces less 4-EPS, could also
ameliorate some of the negative effects of potentially neuro-
toxic metabolites.
The beneficial role of SCFAs in gut health has long been appre-
ciated, but they also play a role in host behavior. For example,
acetate crosses the blood-brain barrier, where it is taken up
and activates hypothalamic neurons (Frost et al., 2014). Intraper-
itoneal administration of acetate suppressed appetite and led to
weight loss. However, although butyrate and acetate were
mostly beneficial (though they appear to contribute to obesity
and diabetes), propionate has been suggested to play a role in
disease; comparisons have been suggested to play a role in dis-
ease: comparisons between a propionic acid-based animal
model of ASD with acquired mitochondrial disorder and a cohort
of 213 children with autism specific disorder suggested abnor-
malities in acyl carnitines via the mitochondrial tricarboxylic
acid cycle (Frye et al., 2013). When injected intraventricularly in
rats, propionate induces behavior with certain features of autism
(MacFabe et al., 2007).
The role of microbial communities in health and disease has
been studied extensively in the past decade, but the microbial
mechanisms driving many of these processes, and their targets
in the mammalian host are yet unknown. Specialized microbial
metabolites originating from the oral, urogenital tract, gastroin-
testinal tract, and skin microbiota may be the next frontier in
elucidating molecular mechanisms of pathogenesis and symbi-
osis (Figures 1 and 3).
Specialized Metabolites from Microbial Isolates
Chemical crosstalk, represented by molecular signaling be-
tween host and associated microbiota, is among the most fasci-
nating new areas in the realm of the human microbiome. The
bioactive molecules produced by the microbiota are likely an
important factor governing the establishment of specific micro-
bial communities in humans. These molecules have been mostly
studied in vitro in pure cultures or cocultures, enabling investiga-
tions of their biological significance. Workflows focused on
directly investigating these natural products from human or ani-
mal samples urgently need to be developed.
Some isolated examples demonstrating the benefits of a uni-
fied framework to investigate natural products are present in
current literature. The quorum-sensing pentapeptide, compe-
tence, and sporulating factor (CSF), produced by Bacillus subti-
lis, helps maintain intestinal homeostasis and protects from
oxidant-induced epithelial cell injury and epithelial barrier
dysfunction when taken up by the organic cation transporter-2.
As a result, CSF induces expression of heat shock protein 27
and survival pathways such as p38 MAP kinase and protein ki-
nase B (Akt) pathways in cultured human colonic epithelial cells
(Fujiya et al., 2007). Similarly, bacterial peptidic pheromones
called competence stimulating peptides produced by human-
derived Streptococcus spp. in coculture experiments regulate
uptake of environmental DNA and prevent hyphae formation by
the oral cavity coinhabitant Candida albicans (Jarosz et al.,2009). Other signaling molecules such as homoserine lactones
mediate interactions between P. aeruginosa andC. albicans, co-
inhabitants of the CF lung community (Hogan et al., 2004).
Biotransformation of CF-associated P. aeruginosa phenazines
by Aspergillus fumigatus has effects on growth and production
of siderophores by A. fumigatus (Moree et al., 2012). Thus,
quorum-sensing molecules likely dictate the status of the micro-
biota and the resulting dynamics.
Although quorum-sensing molecules have been largely
explored in the context of their important roles in host-microbe
or microbe-microbe interactions, ribosomally and nonriboso-
mally synthesized peptides and polyketide classes of specialized
metabolites derived from the human microbiota have not yet
been extensively studied. The biosynthetic pathways encoding
these specialized metabolites are widely present in the genomes
ofmicrobial species, including bacterial species in the human gut
(Cimermancic et al., 2014. Donia et al., 2014). Roles of these
specialized metabolites identified in microbial isolates include
transition of C. albicans from yeast to mycelium by a hybrid non-
ribosomal peptide-polyketide peptidemutanobactin A produced
by oral bacterium Streptococcus mutans (Joyner et al., 2010).
E. coli harboring thepks gene locus for biosynthesis of colibactin,
a putative hybrid nonribosomal peptide-polyketide genotoxin, in-
creases tumor growth in colorectal cells by enhancing the emer-
gence of senescent cells when compared with pks (deletion)
strains (Arthur et al., 2012, Cougnoux et al., 2014). These senes-
cent cells expressed higher levels of growth factors leading to
proliferation of noninfected cells and hence colorectal tumor pro-
motion. A highly conserved biosynthetic gene cluster for burkhol-
deric acid, a polyketide, was found in the genomes of the human
pathogens Burkholderia mallei and Burkholderia pseudomallei
(Franke et al., 2012). These pathogens are considered biowarfare
agents because they can cause high mortality and are rich in
biosynthetic pathways encoding specialized metabolites (Nier-
man et al., 2004; Vial et al., 2007). TheBurkholderia cepacia com-
plex (Bcc) has been demonstrated to produce a large number of
secondary metabolites (Vial et al., 2007). When Bcc infections
occurred in CF patients, the sputum was shown to display
reduced diversity of the polymicrobial infection. These findings
encouraged in vitro studies and screening of the Bcc for antimi-
crobial properties (Lipuma, 2010). These investigations lead to
the discovery of enacyclins, a polyene class of antibiotics, that
displayed potent activity against CF pathogens.
The ribosomally synthesized lantibiotics salivaricins, such as
salivaricin A2, salivaricin B, and salivaricin D among others,
have been isolated from oral bacterium Streptococcus salivarius
from healthy individuals. S. salivarius has been suggested to
have beneficial properties (Hyink et al., 2007; Birri et al., 2012)
and whether these peptides mediate some of the probiotic ef-
fects is unknown. Streptolysin S from Streptococcus pyogenes
is another example of ribosomally produced peptide that
enhanced virulence and occurrence of necrotic lesions in animal
models (Betschel et al., 1998; Lee et al., 2008). Using compara-
tive genomic analysis, biosynthetic pathways similar to the one
utilized for streptolysin S production were found in the genomes
of major food-borne pathogens and led to the characterization
of the biotoxin clostridiolysin S from Clostridium botulinum and
its cousin C. sporogenes, a soil bacterium that can colonize
hosts (Gonzalez et al., 2010; Wikoff et al., 2009). PyroglutamicCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 725
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Lactobacillus plantarum have been shown to reduce production
of proinflammatory cytokine IFNg (Zvanych et al., 2014). Ascaris
suum nematode peptidic molecule, cecropin P1, isolated from
pig intestines and found in various other insects, as well as
cysteine-rich A. suum antibacterial factor peptides isolated
from the human pathogen, Ascaris lumbricoides, have been
shown to possess antimicrobial activity and may help these
pathogens colonize the intestines of associated hosts (Lee
et al., 1989, Andersson et al., 2003). Furthermore, in silico
analyses of genome sequences revealed various biosynthetic
pathways for peptidic specialized metabolites such as thiopep-
tides in human commensal vaginal bacteria Lactobacillus
gasseri and human pathogen Streptococcus pneumonia
(Li et al., 2012). Whether or not members of the microbiota
use this biosynthetic potential to colonize humans and affect
health remains an open question. Human commensal and path-
ogenic microbes also harbor biosynthetic gene clusters for aryl
polyenes and caratenoids that may confer protection against
oxidative stress (Cimermancic et al., 2014). A triterpenoid carte-
noid associated with human pathogen Staphylococcus aureus,
staphyloxanthin, enhances survival under oxidative stress and
prevents killing by neutrophils (Liu et al., 2005; Clauditz et al.,
2006).
Thus, various specialized metabolites are associated with the
human microbiome. Although in silico DNA sequence-based
and in vitro methods have been exploited to investigate metab-
olites that the human microbiota may produce, and to gain in-
sights into the biosynthetic potential and metabolic functions
of these organisms, direct identification of such molecules in
the complex environment of the associated host has not yet
been accomplished. Such in silico methods and experiments
performed in pure cultures or coculture experiments do not
represent the true metabolic capacity of the microbiome
in situ. Thus, future efforts to develop strategies for metabolic
profiling that focus specifically on natural products in fecal mat-
ter, biological fluids such as serum, urine, and intact diseased
host tissues are needed. In this regard, imaging mass spectrom-
etry can be especially valuable in direct molecular analysis of gut
tissue sections (Rath et al., 2012), enabling spatial investigation
of host-microbiome interactions. Molecular networking is an
effective strategy for differentiating metabolites of microbial
and human origin (Garg et al., 2014) from the complex environ-
ment of a CF-associated human lung. Since most specialized
metabolites have associated biosynthetic pathways that are
unique to an organism or a class of organisms, a combination
of metagenome and metatranscriptome sequencing (Quinn
et al., 2014), and high-resolution mass spectrometry-based mo-
lecular networking analysis combined with statistical ap-
proaches will allow the investigation of specialized metabolite-
associated crosstalk between a microbiome and its host.
Although limited to small volatile molecules, gas chromatog-
raphy-mass spectrometry is also useful in connecting metabo-
lites and their origin to physiologically relevant diseased states
(Pleil et al., 2014, Amann et al., 2014). One potential challenge
for future integration of such methodology resides in developing
platforms and algorithms for coanalysis of large volumes of high
density ‘‘Big data’’ generated on different mass spectrometry
based analytical platforms.726 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.Conclusion
With the development of a three-pronged strategy combining
metagenomics, metatranscriptomics, and metabolomics, we
are now entering the new era where we can begin to address
the physiological role of the human microbiome in health and
disease in relation to end products of primary metabolism and
secondary metabolites, with recently emerging emphasis on
microbial natural products, also termed specialized metabolites
in this Perspective. Although a small set of such metabolites
have been shown to modulate host physiology, the vast majority
of suchmetabolites in humans (suggested to be present bymeta-
genome sequencing) have not been investigated. We propose
that the identification of specializedmetabolites, their biotransfor-
mations by themicrobiome and the host, their transport, and their
originviametatranscriptomics, aswell asmetabolomics in combi-
nation with metagenomics, will open new avenues to investigate
underlying mechanisms by which the human microbiome influ-
ences host health and microbial community development.
Subsequent in vivo studies may further substantiate the role of
these metabolites and provide insights into such mechanisms.
Finally, a deeper understanding of the complex chemical cross-
talk between the gut microbiota and humans may advance
potentially revolutionary therapies for immune, metabolic, and
neurologic disorders.ACKNOWLEDGMENTS
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